Skip to content
Research Article Open access CC BY 4.0

Prediction of Timely Decaying Efficiency of Factor VIII Replacement Therapy Using Activated Partial Thromboplastin Time (aPTT) Test in Hemophilia A Patients Undergoing Treatment at the National Hospital of Sri Lanka (NHSL)

Zoysa KKP, Geethal BHH, Ratnamalala V, Kottahachchi DU

Asian Hematology Research Journal · pp. 250–260 · Published 28 Dec 2024

10.9734/ahrj/2024/v7i4188

Abstract

Introduction: Hemophilia A is a genetic disorder caused by Factor VIII deficiency. Prophylactic Factor VIII replacement therapy aims to maintain baseline levels and prevent bleeding. This study aimed to investigate the relationship between Activated Partial Thromboplastin Time (aPTT) and the time since the latest Factor VIII treatment (T) to predict the duration of therapy efficiency. It also aimed to establish a cut-off value for aPTT as an indicator of Elevated Factor VIII Levels (EFL) due to therapy. Patients attending Hemophilia clinic at NHSL were selected for the study (n=61). The study was conducted over 06 months. Methodology: The time from the latest Factor treatment to blood collection (T) was recorded, along with age, weight, and Factor VIII dose from patient records. aPTT was measured using the COATRON-M4 coagulation analyzer. EFL was calculated based on the dose taken. Bivariate correlation analysis was performed to establish associations between aPTT & T and aPTT & EFL. Kaplan-Meier survival analysis was used to determine the maximum recurrence days after the latest Factor VIII dose. Finally, Receiver Operating Characteristic (ROC) curve analysis was conducted to establish aPTT cut-off values as an indicator of EFL in the body. Results: aPTT showed a significant strong positive correlation with T. The Kaplan–Meier survival analysis estimated the median survival time is about 5 days with the initial recurrence of about 2 days, complete recurrence of about 8 days. According to the ROC analysis, the cut-off value of aPTT is estimated as 38.8 s with the sensitivity of 95.2% and specificity of 37.2%. Conclusion: The results indicated that aPTT could predict the maximum duration of Factor VIII therapy efficiency in Hemophilia A patients. Cut-off values for aPTT as an indicator of EFL, determined using ROC curves, were also obtained. However, these findings need validation with a larger patient sample.

Hemophilia A activated partial thromboplastin time test prophylaxis factor VIII replacement therapy

References (16)

  1. 1 WFH Guidelines for the Management of Hemophilia, 3rd edition [DOI]
  2. 2 The past and future of haemophilia: diagnosis, treatments, and its complications [DOI]
  3. 3 International recommendations on the diagnosis and treatment of acquired hemophilia A [DOI]
  4. 4 Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients [DOI]
  5. 5 Coagulation Testing in the Core Laboratory [DOI]
  6. 6 Emicizumab for the treatment of acquired hemophilia A [DOI]
  7. 7 Treatment of hemophilia: a review of current advances and ongoing issues [DOI]
  8. 8 Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. [DOI]
  9. 9 Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients [DOI]
  10. 10 Management of rare coagulation disorders in 2018 [DOI]
  11. 11 Clinical utility and impact of the use of the chromogenic vs one‐stage factor activity assays in haemophilia A and B [DOI]
  12. 12 Overall hemostasis potential and aPTT‐clot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype [DOI]
  13. 13 Acquired hemophilia A: a single-center study of 165 patients [DOI]
  14. 14 Diagnosis of rare bleeding disorders [DOI]
  15. 15 Determining the cut-off value of the APTT mixing test for factor VIII inhibitor: reply [DOI]
  16. 16 Overview of Blood Coagulation and the Pathophysiology of Blood Coagulation Disorders [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

31

Page views

0

PDF downloads

4

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.